Article

Prognostic Role of Tumor Subtype and Germline BRCA Mutation in Advanced Breast Cancer Patients Treated with Palbociclib Plus Endocrine Therapy

2021-08-03

Abstract excerpt

<title>Abstract</title> <p><bold>Background/Aims</bold>: Palbociclib is a cyclin dependent kinase 4 and 6 inhibitor which shows promising effect in hormone receptor positive breast cancer. The purpose of this study is to evaluate the real-world efficacy and toxicity of palbociclib plus endocrine therapy. <bold>Methods</bold>: This is a retrospective study performed in two tertiary referral hospitals in Korea. Adv...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: d1ea395a-fa9b-57d1-a420-5daf2a5b6853
DOI: 10.21203/rs.3.rs-691303/v1

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Prognostic Role of Tumor Subtype and Germline BRCA Mutation in Advanced Breast Cancer Patients Treated with Palbociclib Plus Endocrine TherapyDOI 10.21203/rs.3.rs-691303/v1Read

Prognostic role of tumor subtype and germline BRCA mutation in advanced breast cancer patients treated with palbociclib plus endocrine therapy.Semantic proximity Read

Exploratory analysis of biomarkers associated with clinical outcomes from the study of palbociclib plus endocrine therapy in premenopausal women with hormone receptor-positive, HER2-negative metastatic breast cancerSemantic proximity Read

Comparative biomarker analysis of PALOMA-2/3 trials for palbociclibSemantic proximity Read

Real-World Outcomes of CDK4/6 Inhibitors in Germline BRCA-Mutated Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer: Turkish Oncology Group (TOG) StudySemantic proximity Read

The Present and Future of Clinical Management in Metastatic Breast CancerSemantic proximity Read

Longitudinal multi-omics study of palbociclib resistance in HR-positive/HER2-negative metastatic breast cancerSemantic proximity Read

Identification of a Panel of miRNAs Associated with Resistance to Palbociclib and Endocrine TherapySemantic proximity Read

Exploring the effectiveness of molecular subtypes, biomarkers, and genetic variations as first-line treatment predictors in Asian breast cancer patients: A systematic review and meta-analysisSemantic proximity Read

Deregulated Immune Pathway Associated with Palbociclib Resistance in Preclinical Breast Cancer Models: Integrative Genomics and TranscriptomicsSemantic proximity Read

Randomised, open-label, multicentric phase III trial to evaluate the safety and efficacy of palbociclib in combination with endocrine therapy, guided by ESR1 mutation monitoring in oestrogen receptor-positive, HER2-negative metastatic breast cancer patients: study design of PADA-1.Semantic proximity Read

Survival analysis of patients with early breast cancer associated with PIK3CA mutationSemantic proximity Read

Palbociclib in endocrine-resistant metastatic breast cancer patients: gene polymorphism- based study.Semantic proximity Read